Insight Molecular Diagnostics Inc. — Director's Dealing 2021

Jul 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2021-07-01

Reporting Person: ANDREWS RONALD ASBURY (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-01	Common Stock, no par value	M	65000	—	Acquired	259046	Direct
2021-07-01	Common Stock, no par value	F	15834	—	Disposed	243212	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-01	Restricted Stock Units	$0	M	65000	Disposed		Common Shares (65000)	Direct

Footnotes

F1: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 65,000 Restricted Stock Units.

F2: Restricted Stock Units vested on July 1, 2021.